Page 1 | Search Results | Blood | American Society of Hematology

1-6 of 6

Sort by

Sort Order Select

Journal Articles

Identification of EHMT2 As a New Target in T-Cell Acute Lymphoblastic Leukemia

Samuel Kitara, Angela Su, Claudio Deluca, Franco Aversa, MD, Birgit Knoechel, MDPhD, Jian Jin, PhD, Kimberly Stegmaier, MD, Giovanni Roti, MD PhD

Blood (2017) 130 (Supplement 1): 2548.

https://doi.org/10.1182/blood.V130.Suppl_1.2548.2548

Published: 2017

Journal Articles

Leukemia-Specific Delivery of Mutant NOTCH1 Targeted Therapy

Giovanni Roti, MD PhD, Jun Qi, PhD, Samuel Kitara, Anthony C. Varca, Marta Sanchez-Martin, PhD, Andrew L. Kung, MD PhD, Adolfo A. Ferrando, MD PhD, James E. Bradner, MD, Kimberly Stegmaier, MD

Blood (2016) 128 (22): 889.

https://doi.org/10.1182/blood.V128.22.889.889

Published: 2016

Journal Articles

Selectively Targeting Mutated NOTCH1 with a Folate-Thapsigargin Derivative

Giovanni Roti, MD, Jun Qi, PhD, Angela Su, B.S., Antony Varca, B.S., Jon C Aster, MD PhD, James E. Bradner, Kimberly Stegmaier, MD

Blood (2014) 124 (21): 2158.

https://doi.org/10.1182/blood.V124.21.2158.2158

Published: 2014

Journal Articles

Expression-Based Screen Identifies the Calcium Channel Antagonist Bepridil as a Notch1 Modulator in T-ALL.

Giovanni Roti, MD, Kenneth N. Ross, PhD, Adolfo A. Ferrando, MD, PhD, Stephen C Blacklow, M.D., Ph.D., Jon Aster, MD, PhD, Kimberly Stegmaier, MD

Blood (2009) 114 (22): 366.

https://doi.org/10.1182/blood.V114.22.366.366

Published: 2009

Journal Articles

Chemical Genomic Screen Identifies Ionophores as Modulators of Notch1 in T-ALL

Giovanni Roti, MD, Kenneth N. Ross, PhD, Cristina Mecucci, MD, PhD, Adolfo A. Ferrando, MD, PhD, Jon C. Aster, MD, PhD, Kimberly Stegmaier, MD

Blood (2008) 112 (11): 200.

https://doi.org/10.1182/blood.V112.11.200.200

Published: 2008

Journal Articles

Quantitative Detection of NPM1 Mutations as Marker of Minimal Residual Disease (MRD) in the Large Majority of AML with Normal Karyotype.

Giuseppe Saglio, MD, Paolo Gorello, PhD, Giovanni Cazzaniga, PhD, Enrico Gottardi, Maria Grazia Dell’Oro, MD, Roberto Rosati, PhD, Giovanni Roti, MD, Federica Alberti, PhD, Daniela Diverio, PhD, Massimo Fabrizio Martelli, MD, Francesco Lo Coco, MD, Andrea Biondi, MD, Brunangelo Falini, MD, Cristina Mecucci, MD, PhD

Blood (2005) 106 (11): 225.

https://doi.org/10.1182/blood.V106.11.225.225

Published: 2005

NARROW

Identification of EHMT2 As a New Target in T-Cell Acute Lymphoblastic Leukemia

Leukemia-Specific Delivery of Mutant NOTCH1 Targeted Therapy

Selectively Targeting Mutated NOTCH1 with a Folate-Thapsigargin Derivative

Expression-Based Screen Identifies the Calcium Channel Antagonist Bepridil as a Notch1 Modulator in T-ALL.

Chemical Genomic Screen Identifies Ionophores as Modulators of Notch1 in T-ALL

Quantitative Detection of NPM1 Mutations as Marker of Minimal Residual Disease (MRD) in the Large Majority of AML with Normal Karyotype.

Email alerts

ASH Publications

American Society of Hematology

Identification of EHMT2 As a New Target in T-Cell Acute Lymphoblastic Leukemia

Leukemia-Specific Delivery of Mutant NOTCH1 Targeted Therapy

Selectively Targeting Mutated NOTCH1 with a Folate-Thapsigargin Derivative

Expression-Based Screen Identifies the Calcium Channel Antagonist Bepridil as a Notch1 Modulator in T-ALL.

Chemical Genomic Screen Identifies Ionophores as Modulators of Notch1 in T-ALL

Quantitative Detection of NPM1 Mutations as Marker of Minimal Residual Disease (MRD) in the Large Majority of AML with Normal Karyotype.

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only